Rowland Charles A Jr
SEC Form 4 insider trading activity
Rowland Charles A Jr has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jan 5, 2026.
On the most recent filing, Rowland Charles A Jr is listed as Director at Viking Therapeutics, Inc. Inside the rolling window, Rowland Charles A Jr reported no open-market purchases and 1 open-market sale totaling $2.1M in VKTX.
Companies traded
Other insiders at VKTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rowland Charles A Jr made?
Rowland Charles A Jr has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Rowland Charles A Jr trade?
Rowland Charles A Jr has filed SEC Form 4 disclosures for 1 company, including VKTX.
When was Rowland Charles A Jr's most recent SEC Form 4 filing?
Rowland Charles A Jr's most recent SEC Form 4 filing on Tracefour is dated Jan 5, 2026.
What is Rowland Charles A Jr's total buy and sell value in the current window?
Inside the rolling retention window, Rowland Charles A Jr bought $0 and sold $2.1M based on SEC Form 4 filings.
What was Rowland Charles A Jr's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 60,000 VKTX shares on 2025-10-27, worth $2.1M, per SEC Form 4 filings.